U.S. flag

An official website of the United States government

NM_007327.4(GRIN1):c.1858G>C (p.Gly620Arg) AND Inborn genetic diseases

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
May 15, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000622498.3

Allele description [Variation Report for NM_007327.4(GRIN1):c.1858G>C (p.Gly620Arg)]

NM_007327.4(GRIN1):c.1858G>C (p.Gly620Arg)

Gene:
GRIN1:glutamate ionotropic receptor NMDA type subunit 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
9q34.3
Genomic location:
Preferred name:
NM_007327.4(GRIN1):c.1858G>C (p.Gly620Arg)
Other names:
GRIN1, GLY620ARG, 1858G-C
HGVS:
  • NC_000009.12:g.137162510G>C
  • NG_011507.1:g.28354G>C
  • NM_000832.7:c.1858G>C
  • NM_001185090.2:c.1921G>C
  • NM_001185091.2:c.1921G>C
  • NM_007327.4:c.1858G>CMANE SELECT
  • NM_021569.4:c.1858G>C
  • NP_000823.4:p.Gly620Arg
  • NP_001172019.1:p.Gly641Arg
  • NP_001172020.1:p.Gly641Arg
  • NP_015566.1:p.Gly620Arg
  • NP_067544.1:p.Gly620Arg
  • NC_000009.11:g.140056962G>C
  • NM_007327.3:c.1858G>C
Protein change:
G620R; GLY620ARG
Links:
OMIM: 138249.0012; dbSNP: rs797045047
NCBI 1000 Genomes Browser:
rs797045047
Molecular consequence:
  • NM_000832.7:c.1858G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001185090.2:c.1921G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001185091.2:c.1921G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_007327.4:c.1858G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_021569.4:c.1858G>C - missense variant - [Sequence Ontology: SO:0001583]
Observations:
1

Condition(s)

Name:
Inborn genetic diseases
Identifiers:
MeSH: D030342; MedGen: C0950123

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000742522Ambry Genetics
criteria provided, single submitter

(Ambry exome assertion method (8-5-2015))
Likely pathogenic
(May 15, 2017)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
Hispanicgermlineyes1not providednot provided1not providedclinical testing

Citations

PubMed

Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy.

Lemke JR, Geider K, Helbig KL, Heyne HO, Schütz H, Hentschel J, Courage C, Depienne C, Nava C, Heron D, Møller RS, Hjalgrim H, Lal D, Neubauer BA, Nürnberg P, Thiele H, Kurlemann G, Arnold GL, Bhambhani V, Bartholdi D, Pedurupillay CR, Misceo D, et al.

Neurology. 2016 Jun 7;86(23):2171-8. doi: 10.1212/WNL.0000000000002740. Epub 2016 May 6.

PubMed [citation]
PMID:
27164704
PMCID:
PMC4898312

Glutamate receptor ion channels: structure, regulation, and function.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.

Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. Review. Erratum in: Pharmacol Rev. 2014 Oct;66(4):1141.

PubMed [citation]
PMID:
20716669
PMCID:
PMC2964903
See all PubMed Citations (3)

Details of each submission

From Ambry Genetics, SCV000742522.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1Hispanic1not providednot providedclinical testing PubMed (3)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyes1not providednot provided1not providednot providednot provided

Last Updated: Apr 15, 2024